BioCentury
ARTICLE | Clinical News

AGT-182 regulatory update

July 29, 2013 7:00 AM UTC

ArmaGen said FDA granted Orphan Drug designation for AGT-182 to treat mucopolysaccharidosis type II (MPS-II, Hunter's syndrome). The product is slated to enter clinical testing for MPS-II next half. A...